Novartis Ag

Novartis Pharma Gmbh

Novarts Ag

Hermann Gram

Franco E Di Padova

Thomas Jung

Jean-Michel Rene Rondeau

Wim Van Den Berg

Hans Hofstetter

Margit Jeschke

Timothy Wright

Trevor Mundel

Phil Lowe

Mary Ellen Digan

Philip Lake

Philip Lowe

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating a crystal induced arthropathy using IL-1beta antibodies

An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

IL-17 antagonistic antibodies

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1 beta Compounds'); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds such as IL-1&#x3b2; antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.

Methods of using IL-1&#x3b2; compounds to treat familial mediterranean fever (FMF)

Methods of treating Kawasaki disease using IL-1beta antibodies

This invention relates to a novel use of IL-1&#x25a1;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x25a1; ligand&#x2014;IL-1 receptor interaction, IL-1&#x25a1; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x25a1; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x25a1; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x25a1; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating vascular disease using an IL-1beta Antibody

An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

IL-17 antibodies

This invention relates to a novel use of IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Methods of treating gout using IL-1BETA antibodies

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Use of IL-1beta compounds

Method of treating an auto-inflammatory syndrome with a human IL-1&#x3b2; binding antibody

An IL-1&#x3b2; binding molecule, in particular an antibody to human IL-1&#x3b2;, especially a human antibody to human IL-1&#x3b2; is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

Growing community of inventors

Weil am Rhein, Germany

Hermann Gram